# US 2024/0197701 A1 · Androgen receptor inhibition to treat sepsis and shock

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0197701 A1
- Document ID: US20240197701A1
- Status: Published application
- Kind: A1
- Application number: 18/286,985
- Filed: 2022-04-19
- Published: 2024-06-20
- Earliest claimed: 2021-04-19
- Assignees: Rhode Island Hospital; Applied Biology, Inc.
- Applicants: Rhode Island Hospital; Applied Biology, Inc.
- Inventors: Gerard J. Nau; Carlos G. Wambier; Andy Goren
- Web page: https://patentgrep.com/patent/US20240197701A1

## CPC

- A61K 31/4439: containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole (nicotine A61K31/465)
- A61P 17/02: for treating wounds, ulcers, burns, scars, keloids, or the like
- A61K 31/167: having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
- A61K 31/277: having a ring, e.g. verapamil
- A61K 31/4166: having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
- A61P 31/14: for RNA viruses
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The invention provides a method for applying diarylhydantoin compounds, including flutamide, bicalutamide, enzalutamide, apalutamide, and proxalutamide, to treat sepsis and conditions that mimic sepsis.

## Claims

### Claim 1

A method for applying diarylhydantoin compounds, including flutamide, bicalutamide, enzalutamide, apalutamide, and proxalutamide, to treat sepsis and conditions that mimic sepsis, including COVID-19 infection.

### Claim 2 (depends on 1)

The method of claim 1, wherein the diarylhydantoin compound is proxalutamide.

### Claim 3

A method for applying diarylhydantoin compounds, including flutamide, bicalutamide, enzalutamide, apalutamide, and proxalutamide, to treat traumatic injury.